A Study of The Femoral Popliteal Artery Treated With LEGFLOW OTW

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

172 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) compared with the standard balloon (Admiral Xtreme) for the treatment of stenosis or occlusions in femoral popliteal artery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTW

NCT02962232

Peripheral Artery Disease

UNKNOWN NA

IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA)

NCT01566461

Femoral Artery Stenosis Popliteal Artery Stenosis Femoral Artery Occlusion +1 more

COMPLETED NA

Atherectomy Followed With a Drug Coated Balloon in the Treatment of Long Femoropopliteal Lesions

NCT05868564

Peripheral Arterial Disease

NOT_YET_RECRUITING NA

Safety and Efficacy Study of FemFlow Drug-Eluting Peripheral Balloon Catheter

NCT03683459

Femoral Artery Stenosis Femoral Artery Occlusion Popliteal Arterial Stenosis +1 more

UNKNOWN NA

Evaluation of Paclitaxel in Patients With CLI and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty

NCT02758847

Ischemia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To evaluate the safety and efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) compared with the standard balloon (Admiral Xtreme) for the treatment of stenosis or occlusions in femoral popliteal artery.

This is a prospective, multicenter, prior desiged, randomize and controlled study, planned to enrol 172 subjects. all these subjects will be allocated 1:1 to the LEGFLOW OTW group n=86 and Admiral Xtreme group n=86. and accept the treatment of LEGFLOW and Admiral Xtreme balloon. and followed up at day 0-30, month 6, 12 by DUS and clinical examination. all the endpoint data will be assessed by DUS core-lab, CEC, then be statisticed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LEGFLOW OTW group

in this group subject will be treated by Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) and followed up

Group Type EXPERIMENTAL

Paclitaxel Releasing Peripheral Balloon Dilatation Catheter

Intervention Type DEVICE

in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter

Admiral Xtreme

in this group subject will be treated by Peripheral Balloon Dilatation Catheter (Admiral Xtreme) and followed up

Group Type ACTIVE_COMPARATOR

Peripheral Balloon Dilatation Catheter

Intervention Type DEVICE

in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Paclitaxel Releasing Peripheral Balloon Dilatation Catheter

in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter

Intervention Type DEVICE

Peripheral Balloon Dilatation Catheter

in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LEGFLOW OTW Admiral Xtreme

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years and ≤ 85 years.
2. De novo or restenotic lesions in the femoral popliteal artery due to atherosclerosis, which located in the superficial femoral artery and/or proximal popliteal artery (arterial segment starting at least 1cm beyond the common femoral artery bifurcation to the distal P1 segment of the popliteal artery at the level of the proximal edge of the patella). And the patients are suitable for endovascular therapy with LEGFLOW OTW or Admiral Xtreme.
3. Rutherford class 2 to 5.
4. Target lesion length ≤ 200mm.
5. Target lesion stenosis ≥ 70% or total occlusion, and it can be passed with common manipulation.
6. Reference vessel diameter ≥ 4mm and ≤ 8mm by visual estimate.
7. Target lesion consists of a single of de novo or restenotic lesion, or a adjacent lesion or a combination lesion or multiple lesion which meets the following criteria:

* adjacent lesion: (1) lesion space ≤ 30mm; (2) total lesion length (include lesion space) ≤ 200mm; (3) can be treated as a single lesion.
* Combination lesion: combination lesion is defined as not a chronic total occlusion (CTO), but may include a part of total occlusion (100% stenosis). The total lesion length ≤ 200mm.
* Multiple lesion: (1) lesion space \> 30mm; (2) total lesion length (include lesion space) ≤ 200mm; (3) can be treated as multiple lesions.
8. Angiographic evidence of adequate distal run-off to the foot (at least one native calf vessel is patent, defined as \< 50% diameter stenosis), whether or not this outfolw was re-established by previous intervention.
9. If subject has ipsilateral/contralateral iliac disease that requires treatment during the procedure, the iliac lesions must meet all the following criteria:

* Iliac lesion or occlusion is ≤ 100mm in length;
* must be treated before the target lesion (superficial femoral artery/proximal popliteal artery).
* must be successfully treated before target lesion treatment; success is defined as: (1) residual stenosis \< 30%; (2) free of dissection which can limit blood flow; (3) no occurrence of thrombus, embolization, or other SAE.
10. Life expectancy more than one year.
11. Understands the study objective and is willing to participate and provide the informed consent form, and is willing to comply with specified follow-up evaluations at the specified time points.

Exclusion Criteria

1. Women of childbearing age with negative pregnancy test before procedure, and breastfeeding women.
2. Stroke or STEMI within 30 days prior to the procedure.
3. Either local or systemic thrombolytic therapy within 6 weeks prior to the procedure.
4. Any major surgical operation (operation class ≥ 3) or interventional therapy within 30 days prior to the procedure.
5. Any major selective surgical operation (operation class ≥ 3) or interventional therapy within 30 days prior to the procedure.
6. Restenotic lesions after DCB or bypass surgery.
7. Target limb has been previously treated with bypass surgery.
8. Guidewire must be passed through from the distal part of limb.
9. Known allergies or sensitivities to contrast agent, paclitaxel, anti-platelet, anticoagulants or thrombolytic drugs.
10. Known allergies or sensitivities to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II.
11. Aneurysm located at the target vessel.
12. Acute or sub-acute thrombosis in the target vessel.
13. Angiographic evidence of severe calcification (defined as dense circumferential calcification that makes the target lesion non-dilatable and/or calcificatin that is present on both sides of the vessel wall and that extends more than 5 cntinuous centimeters in length within the target lesion prior to contrast injection or digital subtraction angiography).
14. The bilateral lower limb must be treated in one procedure.
15. Uncorrected bleeding disorder.
16. Renal insufficiency (serum creatinine \>2.5mg/dL or renal dialysis).
17. Stenosis or occlusions due to non-atherosclerosis, such as thrombotic occlusive vasculitis or vasculitis.
18. Septicemia or bacteremia.
19. Patients with severe disease (such as severe chronic obstructive pulmonary disease, malignant tumor, dementia, etc.) or patient's physical condition may affect the compliance with this study.
20. Pre-dilation resulted in a major (≥ Grade D) flow-limiting dissection or residual stenosis \> 70%.
21. Major distal amputation (above the transmetatarsal) in the study limb or non-study limb.
22. Patients who have participated in another investigational drug or device trial that has not completed the primary endpoint.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No